Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies

Nuclear Medicine and Biology

Volumn 35, Issue 4, 2008, Pages 401-411

  Faintuch, Bluma Linkowski ^a   Teodoro, Rodrigo ^a   Duatti, Adriano ^b   Muramoto, Emiko ^a   Faintuch, Salomao ^c   Smith, Charles J ^d  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b UNIVERSITY OF FERRARA   (Italy)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

99mTcN(PNP6) Cys BBN; Bombesin analogs; Prostate cancer; technetium 99m (99mTc) HYNIC BBN

Indexed keywords

2 HYDRAZINONICOTINAMIDE BOMBESIN TC 99M; DIPHOSPHINE CYS BOMBESIN TC 99M; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; CANCER DIAGNOSIS; CLINICAL STUDY; COMPARATIVE STUDY; DRUG DISTRIBUTION; DRUG STABILITY; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PROSTATE CANCER; RADIOCHEMISTRY; URINARY EXCRETION;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; CYSTEINE; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HYDRAZINES; HYDROPHOBICITY; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; NIACINAMIDE; NITROGEN COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PANCREAS; PHOSPHINES; PROSTATE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 43149086083     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.02.005     Document Type: Article

References (29)

1. Heppeler A., Froidevaux S., Eberle A.N., and Maecke H.R. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 7 (2000) 971-994
2. Anastasi A., Erspamer V., and Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians bombesina and alytes. Experientia 27 (1971) 166-169
3. 13] bombesin in the frog Bombina orientalis. J Biol Chem 271 (1996) 7731-7737
4. Smith C.J., Volkert W.A., and Hoffman T.J. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl Med Biol 30 (2003) 861-868
5. Smith C.J., Wolkert W.A., and Hoffman T.J. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32 (2005) 733-740
6. 2: Radiochemical evaluation with co-ligands EDDA (EDDA=ethylenediamine-N,N′-diacetic acid), tricine, and nicotinic acid. Synth React Inorg Met-Org Nano-Met Chem 35 (2005) 43-51
7. Cornelio D.B., Roesler R., and Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol Adv Access (2007) published March 9 on-line
8. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 24 (2004) 357-397
9. 3 bombesin analogues. Nucl Med Biol 34 (2007) 17-28
10. Hoffman T.J., Quinn T.P., and Volkert W.A. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. Nucl Med Biol 28 (2001) 527-539
11. Maina T., Nock B.A., Zhang H., Nikolopoulou A., Waser B., Reubi J.C., et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 46 (2005) 823-830
12. Banerjee S., Pillai M.R.A., and Ramammorthy N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin Nucl Med 31 (2001) 260-277
13. Blok D., Feitsma H.I.J., Kooy Y.M.C., Welling M.M., Ossndorp F., Vermeij P., et al. New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides. Nucl Med Biol 31 (2004) 815
14. Van de Wiele C., Dumont F., Broecke R.V., Oosterlinck W., Cocquyt V., Serreyn R., et al. Technetium-99m RP527, a GRP analogue for visualization of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27 (2000) 1694-1699
15. 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 42 (2001) 1722-1727
16. 99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med 30 (2003) 247-258
17. 99mTc labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiaphosphine-based bifunctional chelating agent. Bioconjug Chem 10 (1999) 254-260
18. -, a new route to a new class of 99mTc-radiopharmaceuticals. Int J Appl Radiat Isot 36 (1985) 133
19. 99mTc-radiopharmaceuticals containing the Tc≡N multiple bond, Int. Appl Radiat Isot 43 (1992) 1329
20. +2 metal fragment: a technetium-nitrido synthon for use with biologically active molecules. The N-(2-methoxyphenyl)piperazil-cysteine analogues as examples. Bioconjug Chem 14 (2003) 1231
21. 99mTc nitrido complex for cerebral imaging. Nucl Med Biol 29 (2002) 665
22. Zinn K.R., Smith C.A., Wu Q., Kirkman R.L., Mountz J.M., Buchsbaum D.J., et al. Imaging adenoviral-mediated gene transfer of gastrin releasing peptide receptor (GRPr) using a Tc-99m-labeled bombesin (BBN) analogue. J Nucl Med 39 (1998) 224P Abstract 994
23. www.cancer.org - accessed April 30, 2007.
24. Markwalder R., and Reubi J.C. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59 (1999) 1152-1159
25. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99 (1999) 2235
26. 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol 29 (2002) 553-560
27. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49 (2008) 318-326
28. Kunstler J.U., Veerendra B., Figueroa S.D., Sieckman G.L., Rold T.L., Hoffman T.J., et al. Organometallic 99mTc(III)′4 + 1′ bombesin(7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem 18 (2007) 1651-1661
29. Smith C.J., Gali H., Sieckman G.L., Higginbotham C., Volkert W.A., and Hoffman T.J. Radiochemical investigations of 99mTc-N3S-X-BBN[7-14]NH2: an in vitro/in vivo structure-activity relationship study where X) 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 14 (2003) 93-102